|
業務類別
|
Biotechnology |
|
業務概覽
|
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market. |
| 公司地址
| 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560 |
| 電話號碼
| +1 212 554-4484 |
| 傳真號碼
| +1 212 554-4531 |
| 公司網頁
| https://www.tgtherapeutics.com |
| 員工數量
| 399 |
| Mr. Sean A. Power |
Chief Financial Officer, Treasurer and Corporate Secretary |
美元 480.00K |
27/02/2026 |
| Mr. Michael S. Weiss |
Chairman of the Board, Chief Executive Officer and President |
美元 875.00K |
27/02/2026 |
|
|
| Mr. Laurence N. Charney |
Lead Independent Director |
27/02/2026 |
| Dr. Sagar Lonial, M.D. |
Independent Director |
27/02/2026 |
| Mr. Daniel Hume |
Independent Director |
27/02/2026 |
| Mr. Kenneth Hoberman |
Independent Director |
27/02/2026 |
| Dr. Yann Echelard, PhD |
Independent Director |
27/02/2026 |
| Mr. Michael S. Weiss |
Chairman of the Board, Chief Executive Officer and President |
27/02/2026 |
|
|
|
|
